Preterm Delivery Clinical Trial
Official title:
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
The objective of the study is to determine if a weekly dose of 17 hydroxyprogesterone
caproate (17P, Makena®) given to women with preterm rupture of the membranes will:
1. increase the probability of continuing the pregnancy until a favorable gestational age.
2. increase the interval between randomization and delivery.
3. decrease neonatal morbidity.
Preterm rupture of the membranes (PROM) is the leading identifiable cause of prematurity and
accounts for about one-third of all preterm deliveries and 18-20% of perinatal deaths in the
USA. When PROM occurs at very early gestational ages, the clinician must make a decision
whether to attempt to prolong the pregnancy or whether to recommend prompt delivery. Both
approaches carry substantial risk. The strategy of continuing the pregnancy is commonly
called "expectant management." During expectant management, gestational age steadily
increases, and the balance naturally shifts toward favoring delivery. Once the gestational
age reaches 34 weeks, the risk of lethal or permanent sequelae of prematurity or minimal, so
most clinicians agree that delivery is warranted. Despite an attempt at expectant management,
the majority of patients with PROM will be delivered within the first week or so.
Unfortunately, no intervention other than antibiotic prophylaxis or corticosteroids have been
shown to prolong latency or reduce neonatal morbidity after PROM. Recent evidence suggests
that prophylactic administration of progesterone medications may reduce the risk of preterm
delivery in women with certain risk factors, notably those with a history of a prior preterm
delivery and those with a shortened cervix discovered by ultrasound examination. Clearly,
women with PROM are at very high risk of preterm delivery, so there is a pressing need to
study whether 17 hydroxyprogesterone caproate (17P) is effective after PROM. Progesterone
might be beneficial after PROM both because it tends to promote uterine quiescence by
suppressing the formation of myometrial gap junctions and because it has anti-inflammatory
properties, suppressing the production of inflammatory cytokines and thereby inhibiting
cervical ripening. Inflammation is a major pathway leading to preterm labor, cervical
dilation & preterm delivery. 17P would seem to be like an ideal candidate for prolongation of
pregnancy after PROM.
This is a double-blinded, placebo-controlled, multicenter, randomized clinical trial of 17P
versus placebo. The primary outcome measure will be the percentage of each group reaching
either a gestational age of 34w0d or documentation of fetal lung maturity at 32w0d to 33w6d.
Secondary outcomes will include the latency period for each group and the percentage of
newborns in each group who have major neonatal morbidity or death.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03304782 -
Fitbit Activity Tracker to Predict Risk of Preterm Birth
|
||
Recruiting |
NCT02420743 -
Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
|
||
Completed |
NCT01665378 -
Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
|
N/A | |
Completed |
NCT00141908 -
Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate
|
Phase 2 | |
Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
Terminated |
NCT03596125 -
Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03123926 -
Spontaneous Preterm Birth Marker Test
|
N/A | |
Completed |
NCT00201643 -
A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
|
Phase 4 | |
Completed |
NCT01353807 -
Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health
|
N/A | |
Terminated |
NCT02545127 -
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
|
Phase 2 | |
Completed |
NCT02371356 -
Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
|
||
Active, not recruiting |
NCT01009723 -
Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers
|
N/A | |
Completed |
NCT00883324 -
Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum
|
N/A | |
Completed |
NCT00615550 -
PREGNANT Short Cervix Trial
|
Phase 3 | |
Completed |
NCT02694679 -
Randomized Controlled Trial of Social Network Targeting in Honduras
|
N/A | |
Completed |
NCT01031017 -
Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies
|
Phase 4 | |
Completed |
NCT00329914 -
Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?
|
Phase 2 | |
Completed |
NCT00331695 -
Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery
|
Phase 4 | |
Completed |
NCT01818518 -
Neonatal Outcome by Reason for Delivery
|
||
Completed |
NCT04637880 -
25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders
|